Brenton Saunders,has been a member of our Board of Directors since May 2021.
In 2023, Mr. Saunders assumed the role of Chairman and CEO of Bausch + Lomb, where he was previously President, CEO and a board member from 2010 to 2013.
Mr. Saunders served as President and CEO of Forest Laboratories, Inc. (formerly NYSE: FRX) from 2013 until its merger with Actavis plc (formerly NYSE: ACT) in 2014. Mr. Saunders became President and CEO of the combined companies. Later in 2014, Mr. Saunders oversaw Actavis’ acquisition of Allergan plc (formerly NYSE: AGN). He held the role of Chairman, President and CEO of Allergan until its acquisition by AbbVie, Inc. (NYSE: ABBV) in 2020. Mr. Saunders then became Chairman, President and CEO of Vesper Healthcare Acquisition Corp. from 2020 to 2021.
Mr. Saunders is currently Chairman of The Beauty Health Company (Nasdaq: SKIN) and Roam. He also serves as a board advisor for Nextech, an Executive Trustee at Mount Sinai Medical Center and a director at Arena AI and Cambrian BioPharma. Mr. Saunders has previous board experience with Cisco Systems (Nasdaq: CSCO), BridgeBio Pharma, Inc. (Nasdaq: BBIO), Osmind, OccuTerra Therapeutics and Glo Pharma.
Mr. Saunders is a passionate advocate for mental health services. He is a long-time contributor to Community Hope, a nonprofit dedicated to providing individuals, families and veterans with support services. Additionally, Mr. Saunders serves on the board of the Child Mind Institute, an organization that supports children with learning disorders and mental health issues. More recently, he broadened his philanthropic efforts to include The Michael J. Fox Foundation for Parkinson’s Research.
Mr. Saunders holds an MBA from the Temple University Fox School of Business and a J.D. from the Temple University Beasley School of Law.
For thought leadership, updates and news from Mr. Saunders, follow him on LinkedIn, X and Instagram.
What is Brent L. Saunders' net worth?
The estimated net worth of Brent L. Saunders is at least $7.17 million as of May 22nd, 2025. Saunders owns 719,156 shares of ARS Pharmaceuticals stock worth more than $7,169,985 as of December 4th. This net worth approximation does not reflect any other assets that Saunders may own. Learn More about Brent L. Saunders' net worth.
How do I contact Brent L. Saunders?
Has Brent L. Saunders been buying or selling shares of ARS Pharmaceuticals?
Who are ARS Pharmaceuticals' active insiders?
Are insiders buying or selling shares of ARS Pharmaceuticals?
In the last twelve months, insiders at the sold shares 23 times. They sold a total of 1,870,472 shares worth more than $27,822,091.20. The most recent insider tranaction occured on November, 13th when COO Brian Dorsey sold 21,828 shares worth more than $190,121.88. Insiders at ARS Pharmaceuticals own 33.5% of the company.
Learn More about insider trades at ARS Pharmaceuticals. Information on this page was last updated on 11/13/2025.
